Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated)
- Generic Name
- Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated)
- Brand Names
- Ixiaro
- Drug Type
- Biotech
- Unique Ingredient Identifier
- DZ854I04ZE
- Indication
用于接种6个月至10周岁的儿童及由非疫区进入疫区的成人可预防乙型脑炎。
- Associated Conditions
- Japanese Encephalitis
A Study to Assess the Safety, Reactogenicity, and Immunogenicity of SK Japanese Encephalitis Messenger Ribonucleic Acid (mRNA) Vaccines (GBP560) in Healthy Adults
Phase 1
Recruiting
- Conditions
- Japanese Encephalitis Virus Disease
- Interventions
- Biological: GBP560-ABiological: GBP560-BBiological: Normal Saline (Placebo)
- First Posted Date
- 2024-11-08
- Last Posted Date
- 2025-03-19
- Lead Sponsor
- SK Bioscience Co., Ltd.
- Target Recruit Count
- 402
- Registration Number
- NCT06680128
- Locations
- 🇦🇺
Nucleus Network - Brisbane (Q Pharm), Brisbane, Australia
🇦🇺Nucleus Network - Melbourne, Melbourne, Australia
🇳🇿New Zealand Clinical Research, Christchurch, Central City, New Zealand
Flavivirus Cross-priming Potential of IMOJEV
- First Posted Date
- 2019-04-18
- Last Posted Date
- 2025-01-31
- Lead Sponsor
- University of Liverpool
- Target Recruit Count
- 19
- Registration Number
- NCT03920111
- Locations
- 🇬🇧
Liverpool University Hospitals NHS Foundation Trust, Liverpool, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath